Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 8/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 8/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 8/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375867 | 0.82 | CHRM3 (0.35) | TPSAB1TPSD1TPSG1CHRM3PRSS1 | |
| SCHEMBL9937440 | 0.76 | PRSS1 (0.39) | TPSAB1TPSD1TPSG1AGTR2RAB9A | |
| SCHEMBL3783660 | 0.76 | KLK7 (0.47) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL12820517 | 0.74 | ALDH1A1 (0.54) | RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL9937907 | 0.73 | AGTR2 (0.46) | TPSAB1TPSD1TPSG1AGTR2PRSS1 | |
| SCHEMBL1424033 | 0.70 | ALOX15 (0.41) | AGTR2 | |
| SCHEMBL5253414 | 0.69 | HSD17B10 (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13604577 | 0.69 | HSD17B10 (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL376354 | 0.68 | TPSAB1 (0.36) | TPSAB1TPSD1TPSG1RAB9APRSS1 | |
| SCHEMBL6857792 | 0.67 | ATM (0.53) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| EP-2079743-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | Chroma Therapeutics Limited (GB) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | TPSAB1 2683/4885TPSD1 1133/4885TPSG1 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.